Treatment and management of myelofibrosis in the era of JAK inhibitors

Myelofibrosis (MF) can present as a primary disorder or evolve from polycythemia vera (PV) or essential thrombocythemia (ET) to post-PV MF or post-ET MF, respectively. MF is characterized by bone marrow fibrosis, splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis, and a collection of...

Descripción completa

Detalles Bibliográficos
Autores principales: Keohane, Clodagh, Radia, Deepti H, Harrison, Claire N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753053/
https://www.ncbi.nlm.nih.gov/pubmed/23990704
http://dx.doi.org/10.2147/BTT.S34942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753053/
https://www.ncbi.nlm.nih.gov/pubmed/23990704
http://dx.doi.org/10.2147/BTT.S34942

Ejemplares similares